ATE209200T1 - N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten - Google Patents

N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten

Info

Publication number
ATE209200T1
ATE209200T1 AT96919941T AT96919941T ATE209200T1 AT E209200 T1 ATE209200 T1 AT E209200T1 AT 96919941 T AT96919941 T AT 96919941T AT 96919941 T AT96919941 T AT 96919941T AT E209200 T1 ATE209200 T1 AT E209200T1
Authority
AT
Austria
Prior art keywords
heteroaryl
sulphonamide derivatives
endotheline antagonists
pyridine
pyridine sulphonamide
Prior art date
Application number
AT96919941T
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Roger John Butlin
Roger James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE209200T1 publication Critical patent/ATE209200T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96919941T 1995-06-07 1996-06-03 N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten ATE209200T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives
PCT/GB1996/001295 WO1996040681A1 (en) 1995-06-07 1996-06-03 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists

Publications (1)

Publication Number Publication Date
ATE209200T1 true ATE209200T1 (de) 2001-12-15

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919941T ATE209200T1 (de) 1995-06-07 1996-06-03 N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten

Country Status (32)

Country Link
US (3) US5866568A (de)
EP (1) EP0832082B1 (de)
JP (1) JP3193058B2 (de)
KR (1) KR100451523B1 (de)
CN (1) CN1097051C (de)
AR (1) AR003132A1 (de)
AT (1) ATE209200T1 (de)
AU (1) AU715041B2 (de)
BR (1) BR9608611A (de)
CA (1) CA2219742C (de)
CZ (1) CZ289387B6 (de)
DE (1) DE69617236T2 (de)
DK (1) DK0832082T3 (de)
EG (1) EG25227A (de)
ES (1) ES2168487T3 (de)
GE (1) GEP20053470B (de)
HK (1) HK1005801A1 (de)
HR (1) HRP960272B1 (de)
HU (1) HUP9802300A3 (de)
IL (1) IL122464A (de)
MX (1) MX9709521A (de)
MY (1) MY114926A (de)
NO (1) NO314503B1 (de)
NZ (1) NZ308619A (de)
PL (1) PL187897B1 (de)
PT (1) PT832082E (de)
RU (1) RU2172738C2 (de)
SK (1) SK282338B6 (de)
TR (1) TR199701502T1 (de)
TW (1) TW340845B (de)
UA (1) UA58494C2 (de)
WO (1) WO1996040681A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
PL197782B1 (pl) 1999-12-31 2008-04-30 Encysive Pharmaceuticals Inc Sulfonoamidy, środek farmaceutyczny i zastosowanie sulfonoamidów
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
US20090209492A1 (en) 2004-11-12 2009-08-20 Trustees Of Tufts College Lipase Inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
MX2008011227A (es) * 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
BRPI0709950A2 (pt) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
NZ576196A (en) * 2006-09-21 2011-12-22 Piramal Life Sciences Ltd Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
KR20100024920A (ko) 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
PL2209501T3 (pl) * 2007-10-12 2012-03-30 Astrazeneca Ab Kompozycja zibotentanu zawierająca mannitol i celulozę mikrokrystaliczną
GEP20135957B (en) 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
ES2453474T3 (es) * 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
WO2021262998A1 (en) * 2020-06-25 2021-12-30 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
US11730735B2 (en) 2020-07-10 2023-08-22 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
JP7531947B2 (ja) 2021-06-22 2024-08-13 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物
TW202423417A (zh) 2022-08-12 2024-06-16 瑞典商阿斯特捷利康公司 用於治療肝硬化伴門靜脈高壓之組合療法
US20240307383A1 (en) 2023-02-08 2024-09-19 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of proteinuria chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1990009787A1 (en) * 1989-02-27 1990-09-07 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
TW270116B (de) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (de) * 1992-02-24 1994-06-01 Squibb & Sons Inc
CA2133090A1 (en) * 1992-04-22 1993-10-28 Wayne L. Cody Endothelin antagonists ii
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
AU4679793A (en) * 1992-07-17 1994-02-14 Smithkline Beecham Corporation Endothelin receptor antagonists
TW287160B (de) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0626174A3 (de) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Verfahren und Zusammensetzung für die Prophylaxe und/oder Behandlung von Organunterfunktion.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
JP3233642B2 (ja) * 1995-04-04 2001-11-26 テキサス・バイオテクノロジー・コーポレイシヨン エンドセリンの活性を調整するチエニル−、フリル−、ピロリル−およびビフェニルスルホンアミドならびにその誘導体

Also Published As

Publication number Publication date
PT832082E (pt) 2002-04-29
US5866568A (en) 1999-02-02
HRP960272A2 (en) 1997-08-31
KR100451523B1 (ko) 2004-12-03
EG25227A (en) 2011-11-17
NO975700D0 (no) 1997-12-05
NO975700L (no) 1997-12-05
UA58494C2 (uk) 2003-08-15
AR003132A1 (es) 1998-07-08
SK168097A3 (en) 1998-05-06
JPH11509175A (ja) 1999-08-17
US6060475A (en) 2000-05-09
GEP20053470B (en) 2005-02-25
AU715041B2 (en) 2000-01-13
HK1005801A1 (en) 1999-01-29
PL324660A1 (en) 1998-06-08
DE69617236D1 (de) 2002-01-03
TR199701502T1 (xx) 1998-03-21
IL122464A (en) 2002-05-23
KR19990022327A (ko) 1999-03-25
CN1097051C (zh) 2002-12-25
HRP960272B1 (en) 2006-06-30
MY114926A (en) 2003-02-28
RU2172738C2 (ru) 2001-08-27
EP0832082A1 (de) 1998-04-01
HUP9802300A2 (hu) 1999-10-28
CA2219742C (en) 2007-01-16
CZ388797A3 (cs) 1998-03-18
NO314503B1 (no) 2003-03-31
IL122464A0 (en) 1998-09-15
CA2219742A1 (en) 1996-12-19
MX9709521A (es) 1998-03-31
US6258817B1 (en) 2001-07-10
HUP9802300A3 (en) 2002-02-28
ES2168487T3 (es) 2002-06-16
PL187897B1 (pl) 2004-10-29
BR9608611A (pt) 1999-05-11
CZ289387B6 (cs) 2002-01-16
CN1192739A (zh) 1998-09-09
JP3193058B2 (ja) 2001-07-30
TW340845B (en) 1998-09-21
EP0832082B1 (de) 2001-11-21
DK0832082T3 (da) 2002-05-21
WO1996040681A1 (en) 1996-12-19
SK282338B6 (sk) 2002-01-07
DE69617236T2 (de) 2002-07-11
AU5840396A (en) 1996-12-30
NZ308619A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
ATE209200T1 (de) N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten
DE69509765D1 (de) N-heterocyclyl sulphonamid-derivate und ihre verwendung als endothelin-antagonisten
ATE205185T1 (de) Benzamid-derivate und deren verwendung als vasopressin-antagonisten
DE69332898T2 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
DE59802439D1 (de) Spiroverbindungen und deren verwendung
DE69622148D1 (de) Chinazozin derivate und deren verwendung
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
DE69736994D1 (de) Ionische Malonsäuredinitril Derivate und deren Verwendung
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE59711847D1 (de) Substituierte aza- und diazacycloheptan- und -cyclooctanverbindungen und deren verwendung
DE69631240D1 (de) Schaltvorrichtung und deren verwendung
DE59506234D1 (de) Pigmentzubereitung und deren Verwendung
DE59601122D1 (de) N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
DE69425905D1 (de) Spinndüse und deren Verwendung
DE59813616D1 (de) Farbige Effektpigmente und deren Verwendung
DE69716062D1 (de) Benzofuran-derivate und deren verwendung
DE69223266D1 (de) Peptidderivate und deren Verwendung
DE69704662D1 (de) Kosmetische waschmittelzusammensetzungen und deren verwendung
DE69729570D1 (de) Fotpempfindliche zusammensetzung und deren verwendung
DE69513307D1 (de) Zusammensetzung und verwendung
DE69713512D1 (de) Substituierte phtalocyanine und deren verwendung
DE69835007D1 (de) Entkoffeinierte mate-extrakte und deren verwendung
DE69510192D1 (de) Substituierte cyclopentylaminderivate und deren verwendung als calcium-kanal antagonisten
DE69610316D1 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification